Hyderabad, India-based Aurobindo Pharma is the latest addition to the world of biosimilars. The company announced that it has acquired 4 biosimilar products from TL Biopharmaceutical AG. Aurobindo plans to develop and commercialize the 4 molecules after it acquires the early stage data from TL.
An important molecule that the company will acquire with this agreement is the biosimilar for bevacizumab (Avastin), a monoclonal antibody developed by Genentech, which has been approved for treatment of a variety of tumor types: metastatic colorectal cancer, non—small cell lung cancer, platinum-resistant ovarian cancer, advanced cervical cancer, metastatic renal cell carcinoma, and recurrent glioblastoma. Bevacizumab is an angiogenesis inhibitor.
Aurobindo’s managing director, N. Govindarajan, said in a statement that the acquisition falls in line with the company’s strategy of establishing a biosimilar portfolio. Regulatory filings for the new acquisitions, 3 of which are in oncology molecules, are expected between 2020 and 2022.